TY - JOUR
T1 - Evaluación de un modelo de diabetes tipo 2 para estudiar la actividad hipoglicemieante de la glibenclamida
AU - Amaya-Chávez, Araceli
AU - Dolores-Ledezma, Emilia
AU - Álvarez-Sánchez, Patricia
AU - Ferreira-Rubio, Guillermo
AU - Gómez-Oliván, Leobardo Manuel
AU - Galar-Martínez, Marcela
PY - 2007/7
Y1 - 2007/7
N2 - A type 2 diabetes model, consisting in the sequential administration of nicotinamide-streptozotocin (225 y 65 mg/kg respectively) to male Wistar rats, was evaluated and subsequently treated with glibenclamide, by acute and subacute tests. Parallel designs were used; the first one to establish the nicotinamide dose which protects against the total destruction of β cells, produced by the streptozotocin and the second one to determine the glibenclamide dose that produces the hypoglycemic effect in the model. The evaluation was done by blood glucose measures and pancreas histological studies. The results showed that this model is adequate for the acute study, but it is necessary to test other nicotinamide doses which may efficiently protect pancreatic β cells from the total destruction produced by the streptozotocin, and that may be useful for subacute or chronic studies, in order to employ it for the efficiency evaluation of other hypoglycemiant drugs.
AB - A type 2 diabetes model, consisting in the sequential administration of nicotinamide-streptozotocin (225 y 65 mg/kg respectively) to male Wistar rats, was evaluated and subsequently treated with glibenclamide, by acute and subacute tests. Parallel designs were used; the first one to establish the nicotinamide dose which protects against the total destruction of β cells, produced by the streptozotocin and the second one to determine the glibenclamide dose that produces the hypoglycemic effect in the model. The evaluation was done by blood glucose measures and pancreas histological studies. The results showed that this model is adequate for the acute study, but it is necessary to test other nicotinamide doses which may efficiently protect pancreatic β cells from the total destruction produced by the streptozotocin, and that may be useful for subacute or chronic studies, in order to employ it for the efficiency evaluation of other hypoglycemiant drugs.
KW - Glibenclamide
KW - Histopathology
KW - Nicotinamide
KW - Streptozotocin
KW - Subacute administration
KW - Type 2 diabetes model
UR - http://www.scopus.com/inward/record.url?scp=34948904438&partnerID=8YFLogxK
M3 - Artículo
SN - 1027-3956
VL - 38
SP - 5
EP - 11
JO - Revista Mexicana de Ciencias Farmaceuticas
JF - Revista Mexicana de Ciencias Farmaceuticas
IS - 3
ER -